Meritz Securities believes that there is a lot of room for share price to rise even after listing on SK Bioscience. It was analyzed that the valuation premium and the incorporation of major indexes of vaccine manufacturers for novel coronavirus infection (Corona 19) will have a positive effect.
On the morning of the 15th of last month, the researchers are looking at a non-clinical sample vaccine for a novel coronavirus infection (Corona 19) being developed at SK Bioscience Research Institute in Seongnam-si, Gyeonggi-do. /yunhap news
On the 18th, Kim Ji-ha, a researcher at Meritz Securities, said, “SK Bioscience has signed a contract with AstraZeneca and Novavex corona vaccine CMO (consignment production) and CDMO (consignment development production) and a license agreement for domestic supply of Nova Vax vaccine.” In a severe shortage situation, it is possible to win additional CMO contracts using the spare amount.”
Researcher Kim said, “We are developing two candidate substances for corona vaccine with synthetic antigen method, respectively, in Phase 1 and Phase 1/2 clinical trials, respectively. It is possible to announce the results.” He added, “We have also signed a joint development agreement with Sanofi to develop a next-generation pneumococcal vaccine.”
On the other hand, on the first day of listing, if SK Bioscience doubles the initial price of the public offering, and then raises to the upper limit and closes the so-called’dasang’, the stock price will be 169,000 won. The public offering is 104,000 won higher than 65,000 won, and the rate of return is 160%. Last year, all major public offerings such as SK Biopharm and Kakao Games recorded awards.
